AKT1 and neoplasm: Figure 4A shows that the combination of TUSC2 intravenous injection and MK2206 treatment was significantly superior (P<0.05) in reducing tumor volumes than either agent alone. The mean tumor volume was 363.8±165.4 mm3, compared with 1171.5±293.7 mm3 and 926.4±250.5 mm3 in those groups receiving intravenous TUSC2 or MK2206 treatment alone, respectively. Immunohistochemical (IHC) staining of tumor tissue sections showed effective TUSC2 delivery to the lungs and marked inhibition of p-AKT expression by MK2206 (Fig. 4B).